Intellipharmaceutics International Inc. (IPCIF)
OTCMKTS: IPCIF · Delayed Price · USD
0.0600
0.00 (0.00%)
May 6, 2024, 12:32 PM EDT - Market open
IPCIF Revenue
Intellipharmaceutics International had revenue of $904.95K in the twelve months ending August 31, 2023, with 386.82% growth year-over-year. Revenue in the quarter ending August 31, 2023 was $68.72K with 260.38% year-over-year growth. In the fiscal year ending November 30, 2022, Intellipharmaceutics International had annual revenue of $65.73K.
Revenue (ttm)
$904.95K
Revenue Growth
+386.82%
P/S Ratio
2.69
Revenue / Employee
$82,268
Employees
11
Market Cap
2.43M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2022 | 65.73K | - | - |
Nov 30, 2021 | 65.73K | -1.34M | -95.31% |
Nov 30, 2020 | 1.40M | - | - |
Nov 30, 2019 | 1.40M | -311.21K | -18.17% |
Nov 30, 2018 | 1.71M | -3.79M | -68.88% |
Nov 30, 2017 | 5.50M | 3.26M | 144.97% |
Nov 30, 2016 | 2.25M | -1.85M | -45.11% |
Nov 30, 2015 | 4.09M | -4.68M | -53.32% |
Nov 30, 2014 | 8.77M | 7.24M | 474.13% |
Nov 30, 2013 | 1.53M | 1.42M | 1,326.33% |
Nov 30, 2012 | 107.09K | -394.72K | -78.66% |
Nov 30, 2011 | 501.81K | -957.57K | -65.61% |
Nov 30, 2010 | 1.46M | - | - |
Nov 30, 2008 | 0 | - | - |
Nov 30, 2007 | 0 | - | - |
Nov 30, 2006 | 0 | - | - |
Nov 30, 2005 | 0 | - | - |
Nov 30, 2004 | 0 | - | - |
Nov 30, 2003 | 0 | - | - |
Nov 30, 2002 | 0 | - | - |
Nov 30, 2001 | 1.00K | 0.21 | 0.02% |
Nov 30, 2000 | 999.82 | -99.06K | -99.00% |
Nov 30, 1999 | 100.06K | 221.19 | 0.22% |
Nov 30, 1998 | 99.84K | 29.56K | 42.07% |
Nov 30, 1997 | 70.27K | -3.94K | -5.31% |
Nov 30, 1996 | 74.21K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 81.80B |
Merck & Co. | 60.12B |
AbbVie | 54.40B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
IPCIF News
- 2 months ago - Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan - Accesswire
- 2 months ago - Intellipharmaceutics Announces Cease Trade Order - Accesswire
- 2 months ago - Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form - Accesswire
- 3 months ago - Intellipharmaceutics International Inc. Announces Stock Option Grant - Accesswire
- 4 months ago - Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange - Accesswire
- 7 months ago - Intellipharmaceutics Announces Third Quarter 2023 Results - Accesswire
- 8 months ago - Intellipharmaceutics Reports Director Election Results - Accesswire
- 10 months ago - Intellipharmaceutics Announces Second Quarter 2023 Results - Accesswire